Retatrutide, by Soma Corp., is gaining significant attention as a novel therapy for weight management . This dual-action compound merges the properties of a GLP-1 receptor activator and a GIP receptor stimulant, intended to effectively promote weight loss but also target related metabolic conditions . Initial clinical trials have demonstrated promi